83 related articles for article (PubMed ID: 8816060)
1. [Advances in the pathogenesis, biology, and management of multiple myeloma].
Kosaka M
Rinsho Byori; 1996 Aug; 44(8):743-9. PubMed ID: 8816060
[TBL] [Abstract][Full Text] [Related]
2. Multiple myeloma: new aspects of biology and treatment.
Ozaki S; Kosaka M
J Med Invest; 1998 Feb; 44(3-4):127-36. PubMed ID: 9597800
[TBL] [Abstract][Full Text] [Related]
3. Advances in the biology of multiple myeloma: therapeutic applications.
Anderson K
Semin Oncol; 1999 Oct; 26(5 Suppl 13):10-22. PubMed ID: 10528890
[TBL] [Abstract][Full Text] [Related]
4. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma.
Barillé S; Bataille R; Amiot M
Eur Cytokine Netw; 2000 Dec; 11(4):546-51. PubMed ID: 11125296
[TBL] [Abstract][Full Text] [Related]
5. Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells.
Martinelli G; Terragna C; Lemoli RM; Cavo M; Benni M; Motta MR; Amabile M; Ottaviani E; Testoni N; de Vivo A; Tura S
Haematologica; 1999 May; 84(5):397-404. PubMed ID: 10329917
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
7. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
Westendorf JJ; Jelinek DF
J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of multiple myeloma.
Huang YW; Vitetta ES
Stem Cells; 1995 Mar; 13(2):123-34. PubMed ID: 7540468
[TBL] [Abstract][Full Text] [Related]
9. Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation.
Kiel K; Cremer FW; Rottenburger C; Kallmeyer C; Ehrbrecht E; Atzberger A; Hegenbart U; Goldschmidt H; Moos M
Bone Marrow Transplant; 1999 May; 23(10):1019-27. PubMed ID: 10373068
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulins D and M multiple myeloma variants are heavily mutated.
Juge-Morineau N; Heirman C; Bakkus M; Van Camp B; Malfait R; Harousseau JL; Thielemans K; Bataille R
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2501-6. PubMed ID: 9815653
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma.
Ballester OF; Fang T; Raptis A; Ballester G; Wilcox P; Hiemenz J; Tan B
Bone Marrow Transplant; 2004 Sep; 34(5):419-23. PubMed ID: 15286696
[TBL] [Abstract][Full Text] [Related]
12. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
[TBL] [Abstract][Full Text] [Related]
13. Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma.
Gadó K; Domján G; Hegyesi H; Falus A
Cell Biol Int; 2000; 24(4):195-209. PubMed ID: 10816321
[TBL] [Abstract][Full Text] [Related]
14. [The role of biotherapy in multiple myeloma].
Petrucci MT; Tafuri A; Mandelli F
Recenti Prog Med; 2000 Oct; 91(10):488-93. PubMed ID: 11072735
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of humanized anti-interleukin-6 receptor antibody: antitumor activity in xenograft model of multiple myeloma.
Tsunenari T; Akamatsu K; Kaiho S; Sato K; Tsuchiya M; Koishihara Y; Kishimoto T; Ohsugi Y
Anticancer Res; 1996; 16(5A):2537-44. PubMed ID: 8917348
[TBL] [Abstract][Full Text] [Related]
16. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
17. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
18. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.
Wang YD; De Vos J; Jourdan M; Couderc G; Lu ZY; Rossi JF; Klein B
Oncogene; 2002 Apr; 21(16):2584-92. PubMed ID: 11971193
[TBL] [Abstract][Full Text] [Related]
19. [Autologous transplantation of peripheral hematopoietic cells in a patient with multiple myeloma and renal insufficiency].
Krejcí M; Doubek M; Adam Z; Hájek R; Vorlícek J; Mayer J
Vnitr Lek; 1997 Nov; 43(11):756-8. PubMed ID: 9650509
[TBL] [Abstract][Full Text] [Related]
20. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma.
Reichardt VL; Okada CY; Stockerl-Goldstein KE; Bogen B; Levy R
Biol Blood Marrow Transplant; 1997 Aug; 3(3):157-63. PubMed ID: 9310193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
